IP Library Granted Patent US 9,974,594
Granted Patent B2
US 9,974,594 · App. 14/467,914 · Granted May 22, 2018

System and method for sensing tissue characteristics

Inventors: Kristin D. Johnson (Louisville, CO); Kyle R. Rick (Boulder, CO); Christopher A. Valentine (Boulder, CO); Mika N. Sinanan (Brier, WA)
Assignee: COVIDIEN LP
A61B18/042A61B2018/00166A61B2018/00577A61B2018/00642A61B2018/00755A61B2018/00875A61B2018/00922A61B2218/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,594
App. No.
14/467,914
Granted
May 22, 2018
Kind
B2
Abstract

A medical device for treating and analyzing tissue includes a plasma applicator having a housing. The housing includes a substantially tubular shape and defines a lumen therethrough. The lumen is in fluid communication with an ionizable media source configured to supply ionizable media thereto. The applicator also includes one or more electrodes coupled to the housing. The electrodes are adapted to couple to a power source configured to energize the electrodes to ignite the ionizable media to form a plasma plume for treating tissue. The device also includes an effluent-collection attachment coupled to the plasma applicator. The effluent-collection attachment is configured to collect a portion of a plasma effluent.

Claims (30)

1. A method for treatment and analysis of tissue comprising:

generating and supplying a plasma plume to tissue through a plasma applicator to form a plasma effluent;

collecting a portion of the plasma effluent through an effluent-collection attachment by filtering the portion of the plasma effluent through a plurality of filters;

analyzing the portion of the plasma effluent with a spectrometer to generate plasma plume data; and

processing the plasma plume data to determine at least one of a type of the tissue or effectiveness of energy delivery to the tissue.

2. A method according to claim 1 , further comprising:

adding a contrast agent to the tissue, wherein the contrast agent has different uptake rates for malignant and healthy tissue.

3. A method according to claim 2 , wherein processing the plasma plume data further includes determining an amount of malignant tissue based on a presence of the contrast agent in the plasma plume.

4. A method according to claim 1 , wherein collecting the portion of the plasma effluent further includes passing the portion of the plasma effluent through a plasma chamber.

5. A method according to claim 1 , wherein collecting the portion of the plasma effluent further includes supplying a negative pressure source to the effluent-collection attachment to provide for a flow of the portion of the plasma effluent through the effluent-collection attachment.

6. A method for treatment and analysis of tissue comprising:

generating and supplying a plasma plume to tissue through a plasma applicator to form a plasma effluent;

collecting a portion of the plasma effluent through an effluent-collection attachment;

analyzing the portion of the plasma effluent with a spectrometer to generate plasma plume data; and

processing the plasma plume data to determine at least one of a type of the tissue or effectiveness of energy delivery to the tissue by determining a ratio of malignant to normal tissue.

7. A method according to claim 6 , further comprising:

determining progression of malignant tissue based on the ratio; and

terminating generation and supply of the plasma plume based on the determined progression.

8. A method for treatment and analysis of tissue comprising:

generating and supplying a plasma plume to tissue having malignant and normal cells through a plasma applicator to form a plasma effluent;

collecting a portion of the plasma effluent through an effluent-collection attachment;

analyzing the portion of the plasma effluent with a spectrometer to generate plasma plume data;

processing the plasma plume data to determine a ratio of malignant to normal tissue; and

determining progression of malignant tissue based on the ratio and terminating generation and supply of the plasma plume based on the determined progression.

9. A method according to claim 8 , further comprising:

adding a contrast agent to the tissue, wherein the contrast agent has different uptake rates for malignant and healthy tissue.

10. A method according to claim 9 , wherein processing the plasma plume data further includes determining an amount of malignant tissue based on a presence of the contrast agent in the plasma plume.

11. A method according to claim 8 , wherein collecting the portion of the plasma effluent further includes filtering the portion of the plasma effluent through a plurality of filters.

12. A method according to claim 8 , wherein collecting the portion of the plasma effluent further includes passing the portion of the plasma effluent through a plasma chamber.

13. A method according to claim 8 , wherein collecting the portion of the plasma effluent further includes supplying a negative pressure source to the effluent-collection attachment to provide for a flow of the portion of the plasma effluent through the effluent-collection attachment.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2014
From: JOHNSON, KRISTIN D.; RICK, KYLE R.; VALENTINE, CHRISTOPHER A.; SINANAN, MIKA N.
To: TYCO HEALTHCARE GROUP LP
Reel/Frame 033603/0897 →
CHANGE OF NAME Recorded Aug 25, 2014
From: TYCO HEALTHCARE GROUP LP
To: COVIDIEN LP
Reel/Frame 033609/0705 →
Continuity (2)
Division 12791100 · Jun 1, 2010
Related Publication 20140364849A1 · Dec 11, 2014